NEUP
NASDAQ · Biotechnology
Neuphoria Therapeutics Inc
$4.38
+0.31 (+7.62%)
Open$4.19
Previous Close$4.07
Day High$4.44
Day Low$4.15
52W High$21.40
52W Low$3.65
Volume—
Avg Volume58.5K
Market Cap22.64M
P/E Ratio—
EPS$-2.12
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+237.7% upside
Current
$4.38
$4.38
Target
$14.79
$14.79
$9.77
$14.79 avg
$16.23
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 52.99M | 5.17M | 4.87M |
| Net Income | -1,252,990 | -354,866 | -256,361 |
| Profit Margin | -2.4% | -6.9% | -5.3% |
| EBITDA | 250.0K | -507,265 | -425,609 |
| Free Cash Flow | — | -183,163 | -132,058 |
| Rev Growth | +696.2% | -7.1% | +6.1% |
| Debt/Equity | 0.00 | 0.39 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |